FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2054589128> ?p ?o ?g. }

• W2054589128 endingPage "3075" @default.
• W2054589128 startingPage "3061" @default.
• W2054589128 abstract "Results from pivotal registration trials in major depressive disorder cohere with outcomes from effectiveness studies indicating that the majority of individuals receiving single-agent pharmacotherapy fail to achieve and sustain symptomatic remission. Several factors provided the impetus for this review: suboptimal efficacy with existing pharmacotherapy for major depressive disorder, quetiapine XR efficacy in the acute and maintenance treatment of bipolar depression, emerging pharmacodynamic evidence that quetiapine XR (and/or its metabolites) uniquely engages monoaminergic systems salient to symptom relief in depressive syndromes, the increasing use of second-generation antipsychotics in the treatment of major depressive disorder and the recent FDA review of quetiapine XR in major depressive disorder. Studies reviewed herein are pivotal registration trials that evaluated the acute and maintenance efficacy and tolerability of quetiapine XR (as monotherapy and as adjunctive treatment) in major depressive disorder. In addition, we also review recent investigations characterizing the pharmacodynamic effect of quetiapine's principal active metabolite, norquetiapine. All studies were obtained from AstraZeneca (Wilmington, DE, USA) and have been presented at national/international scientific meetings. Taken together, extant studies demonstrated that quetiapine XR (50 - 300 mg) provides rapid and sustained symptomatic improvement in the acute and maintenance treatment of major depressive disorder. Quetiapine XR may also offer advantages relative to duloxetine in time to onset of antidepressant action. The major limitations of quetiapine XR use in major depressive disorder relate to weight gain and disrupted glucose/lipid homeostasis as well as sedation/somnolence. Quetiapine XR has tolerability advantages compared with duloxetine on measures of sexual dysfunction. The data from the studies reviewed herein also indicate that quetiapine XR poses a low risk for extrapyramidal side effects in middle-aged and elderly individuals with major depressive disorder." @default.
• W2054589128 created "2016-06-24" @default.
• W2054589128 creator A5013738913 @default.
• W2054589128 creator A5019239227 @default.
• W2054589128 creator A5026591760 @default.
• W2054589128 creator A5027917827 @default.
• W2054589128 creator A5032497184 @default.
• W2054589128 creator A5037883802 @default.
• W2054589128 creator A5068850044 @default.
• W2054589128 creator A5072873693 @default.
• W2054589128 creator A5091856505 @default.
• W2054589128 date "2009-12-01" @default.
• W2054589128 modified "2023-10-04" @default.
• W2054589128 title "Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials" @default.
• W2054589128 cites W1944222706 @default.
• W2054589128 cites W1995358122 @default.
• W2054589128 cites W2007880575 @default.
• W2054589128 cites W2012655610 @default.
• W2054589128 cites W2021744708 @default.
• W2054589128 cites W2032446177 @default.
• W2054589128 cites W2041948429 @default.
• W2054589128 cites W2074852398 @default.
• W2054589128 cites W2113208497 @default.
• W2054589128 cites W2125073267 @default.
• W2054589128 cites W2149402043 @default.
• W2054589128 cites W2153381163 @default.
• W2054589128 cites W2165044084 @default.
• W2054589128 cites W2166079129 @default.
• W2054589128 doi "https://doi.org/10.1517/14656560903448837" @default.
• W2054589128 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19954275" @default.
• W2054589128 hasPublicationYear "2009" @default.
• W2054589128 type Work @default.
• W2054589128 sameAs 2054589128 @default.
• W2054589128 citedByCount "32" @default.
• W2054589128 countsByYear W20545891282012 @default.
• W2054589128 countsByYear W20545891282013 @default.
• W2054589128 countsByYear W20545891282014 @default.
• W2054589128 countsByYear W20545891282015 @default.
• W2054589128 countsByYear W20545891282016 @default.
• W2054589128 countsByYear W20545891282017 @default.
• W2054589128 countsByYear W20545891282019 @default.
• W2054589128 countsByYear W20545891282021 @default.
• W2054589128 countsByYear W20545891282022 @default.
• W2054589128 crossrefType "journal-article" @default.
• W2054589128 hasAuthorship W2054589128A5013738913 @default.
• W2054589128 hasAuthorship W2054589128A5019239227 @default.
• W2054589128 hasAuthorship W2054589128A5026591760 @default.
• W2054589128 hasAuthorship W2054589128A5027917827 @default.
• W2054589128 hasAuthorship W2054589128A5032497184 @default.
• W2054589128 hasAuthorship W2054589128A5037883802 @default.
• W2054589128 hasAuthorship W2054589128A5068850044 @default.
• W2054589128 hasAuthorship W2054589128A5072873693 @default.
• W2054589128 hasAuthorship W2054589128A5091856505 @default.
• W2054589128 hasConcept C118552586 @default.
• W2054589128 hasConcept C197934379 @default.
• W2054589128 hasConcept C2776412080 @default.
• W2054589128 hasConcept C2776921671 @default.
• W2054589128 hasConcept C2778375690 @default.
• W2054589128 hasConcept C2779177272 @default.
• W2054589128 hasConcept C2780051608 @default.
• W2054589128 hasConcept C2780494398 @default.
• W2054589128 hasConcept C2780616385 @default.
• W2054589128 hasConcept C2780634440 @default.
• W2054589128 hasConcept C2780733359 @default.
• W2054589128 hasConcept C2911140283 @default.
• W2054589128 hasConcept C558461103 @default.
• W2054589128 hasConcept C71924100 @default.
• W2054589128 hasConcept C98274493 @default.
• W2054589128 hasConceptScore W2054589128C118552586 @default.
• W2054589128 hasConceptScore W2054589128C197934379 @default.
• W2054589128 hasConceptScore W2054589128C2776412080 @default.
• W2054589128 hasConceptScore W2054589128C2776921671 @default.
• W2054589128 hasConceptScore W2054589128C2778375690 @default.
• W2054589128 hasConceptScore W2054589128C2779177272 @default.
• W2054589128 hasConceptScore W2054589128C2780051608 @default.
• W2054589128 hasConceptScore W2054589128C2780494398 @default.
• W2054589128 hasConceptScore W2054589128C2780616385 @default.
• W2054589128 hasConceptScore W2054589128C2780634440 @default.
• W2054589128 hasConceptScore W2054589128C2780733359 @default.
• W2054589128 hasConceptScore W2054589128C2911140283 @default.
• W2054589128 hasConceptScore W2054589128C558461103 @default.
• W2054589128 hasConceptScore W2054589128C71924100 @default.
• W2054589128 hasConceptScore W2054589128C98274493 @default.
• W2054589128 hasIssue "18" @default.
• W2054589128 hasLocation W20545891281 @default.
• W2054589128 hasLocation W20545891282 @default.
• W2054589128 hasOpenAccess W2054589128 @default.
• W2054589128 hasPrimaryLocation W20545891281 @default.
• W2054589128 hasRelatedWork W1705397834 @default.
• W2054589128 hasRelatedWork W1922671966 @default.
• W2054589128 hasRelatedWork W1985179946 @default.
• W2054589128 hasRelatedWork W2032448496 @default.
• W2054589128 hasRelatedWork W2044907929 @default.
• W2054589128 hasRelatedWork W2071307001 @default.
• W2054589128 hasRelatedWork W2091054476 @default.
• W2054589128 hasRelatedWork W2093470593 @default.
• W2054589128 hasRelatedWork W2130611514 @default.
• W2054589128 hasRelatedWork W2141441326 @default.

• next